Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial

Autor: Corrie, PG, Marshall, A, Nathan, PD, Lorigan, P, Gore, M, Tahir, S, Faust, G, Kelly, CG, Marples, M, Danson, SJ, Marshall, E, Houston, SJ, Board, RE, Waterston, AM, Nobes, JP, Harries, M, Kumar, S, Goodman, A, Dalgleish, A, Martin-Clavijo, A, Westwell, S, Casasola, R, Chao, D, Maraveyas, A, Patel, PM, Ottensmeier, CH, Farrugia, D, Humphreys, A, Eccles, B, Young, G, Barker, EO, Harman, C, Weiss, M, Myers, KA, Chhabra, A, Rodwell, SH, Dunn, JA, Middleton, MR, AVAST-M Investigators, Nathan, P, Dziewulski, P, Holikova, S, Panwar, U, Thomas, A, Corrie, P, Sirohi, B, Kelly, C, Middleton, M, Danson, S, Lester, J, Ajaz, M, Houston, S, Board, R, Eaton, D, Waterston, A, Nobes, J, Loo, S, Gray, G, Stubbings, H, Marsden, J, Patel, P, Ottensmeier, C, Dega, R, Herbert, C, Price, C, Brunt, M, Scott-Brown, M, Hamilton, J, Hayward, RL, Smyth, J, Woodings, P, Nayak, N, Burrows, L, Wolstenholme, V, Wagstaff, J, Nicolson, M, Wilson, A, Barlow, C, Scrase, C, Podd, T, Gonzalez, M, Stewart, J, Highley, M, Grumett, S, Talbot, T, Nathan, K, Coltart, R, Gee, B

Publikováno v: Annals of Oncology
Corrie, P G, Marshall, A, Nathan, P D, Lorigan, P, Gore, M, Tahir, S, Faust, G, Kelly, C G, Marples, M, Danson, S J, Marshall, E, Houston, S J, Board, R E, Waterston, A M, Nobes, J P, Harries, M, Kumar, S, Goodman, A, Dalgleish, A, Martin-Clavijo, A, Westwell, S, Casasola, R, Chao, D, Maraveyas, A, Patel, P M, Ottensmeier, C H, Farrugia, D, Humphreys, A, Eccles, B, Young, G, Barker, E O, Harman, C, Weiss, M, Myers, K A, Chhabra, A, Rodwell, S H, Dunn, J A & Middleton, M R 2019, ' Adjuvant bevacizumab for melanoma patients at high risk of recurrence : survival analysis of the AVAST-M trial ', Annals of Oncology, vol. 30, no. 12, pp. 2013-2014 . https://doi.org/10.1093/annonc/mdz237
Corrie, P G, Marshall, A, Nathan, P D, Lorigan, P, Gore, M, Tahir, S, Faust, G, Kelly, C G, Marples, M, Danson, S J, Marshall, E, Houston, S J, Board, R E, Waterston, A M, Nobes, J P, Harries, M, Kumar, S, Goodman, A, Dalgleish, A, Martin-Clavijo, A, Westwell, S, Casasola, R, Chao, D, Maraveyas, A, Patel, P M, Ottensmeier, C H, Farrugia, D, Humphreys, A, Eccles, B, Young, G, Barker, E O, Harman, C, Weiss, M, Myers, K A, Chhabra, A, Rodwell, S H, Dunn, J A & Middleton, M R 2018, ' Adjuvant bevacizumab for melanoma patients at high risk of recurrence : survival analysis of the AVAST-M trial ', Ann Oncol., vol. 29, no. 8, pp. 1843-1852 . https://doi.org/10.1093/annonc/mdy229

Background Bevacizumab is a recombinant humanised monoclonal antibody to vascular endothelial growth factor shown to improve survival in advanced solid cancers. We evaluated the role of adjuvant bevacizumab in melanoma patients at high risk of recurr

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::106bd17e6b41935f029db129ae87e05b
http://europepmc.org/articles/PMC6096737

Clinical Outcomes and Risk Stratification of Early-Stage Melanoma Micrometastases From an International Multicenter Study: Implications for the Management of American Joint Committee on Cancer IIIA Disease.

Autor: Moncrieff MD; Norfolk and Norwich University Hospital NHS Trust, Norwich, United Kingdom., Lo SN; Melanoma Institute of Australia, The University of Sydney, Sydney, New South Wales, Australia., Scolyer RA; Melanoma Institute of Australia, The University of Sydney, Sydney, New South Wales, Australia.; Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.; NSW Health Pathology, Sydney, New South Wales, Australia.; Royal Prince Alfred Hospital, Sydney, New South Wales, Australia., Heaton MJ; Norfolk and Norwich University Hospital NHS Trust, Norwich, United Kingdom., Nobes JP; Norfolk and Norwich University Hospital NHS Trust, Norwich, United Kingdom., Snelling AP; Norfolk and Norwich University Hospital NHS Trust, Norwich, United Kingdom., Carr MJ; H. Lee Moffitt Cancer Center, Tampa, FL., Nessim C; The Ottawa Hospital, University of Ottawa, Ottawa, Ontario, Canada., Wade R; Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom., Peach AH; Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom., Kisyova R; North Bristol Hospital NHS Trust, Bristol, United Kingdom., Mason J; North Bristol Hospital NHS Trust, Bristol, United Kingdom., Wilson ED; North Bristol Hospital NHS Trust, Bristol, United Kingdom., Nolan G; St Helens and Knowsley NHS Teaching Hospitals Trust, Liverpool, United Kingdom., Pritchard Jones R; St Helens and Knowsley NHS Teaching Hospitals Trust, Liverpool, United Kingdom., Johansson I; Sahlgrenska Centre for Cancer Research, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.; Sahlgrenska University Hospital, Gothenburg, Sweden., Olofsson Bagge R; Sahlgrenska Centre for Cancer Research, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.; Sahlgrenska University Hospital, Gothenburg, Sweden., Wright LJ; United Hospitals of Leicester NHS Trust, Leicester, United Kingdom., Patel NG; United Hospitals of Leicester NHS Trust, Leicester, United Kingdom., Sondak VK; H. Lee Moffitt Cancer Center, Tampa, FL., Thompson JF; Melanoma Institute of Australia, The University of Sydney, Sydney, New South Wales, Australia.; Royal Prince Alfred Hospital, Sydney, New South Wales, Australia., Zager JS; H. Lee Moffitt Cancer Center, Tampa, FL.

Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2022 Dec 01; Vol. 40 (34), pp. 3940-3951. Date of Electronic Publication: 2022 Jul 18.

Commentary on the British Association of Dermatologists UK basal cell carcinoma guidelines 2021: all together now ….

Autor: Moncrieff MD; Department of Plastic and Reconstructive Surgery, Norfolk and Norwich University Hospital, Norwich, UK., Nobes JP; Department of Oncology, Norfolk and Norwich University Hospital, Norwich, UK.

Publikováno v: The British journal of dermatology [Br J Dermatol] 2021 Nov; Vol. 185 (5), pp. 877. Date of Electronic Publication: 2021 Sep 02.

Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial.

Autor: Corrie PG, Marshall A, Nathan PD, Lorigan P, Gore M, Tahir S, Faust G, Kelly CG, Marples M, Danson SJ, Marshall E, Houston SJ, Board RE, Waterston AM, Nobes JP, Harries M, Kumar S, Goodman A, Dalgleish A, Martin-Clavijo A, Westwell S, Casasola R, Chao D, Maraveyas A, Patel PM, Ottensmeier CH, Farrugia D, Humphreys A, Eccles B, Young G, Barker EO, Harman C, Weiss M, Myers KA, Chhabra A, Rodwell SH, Dunn JA, Middleton MR

Publikováno v: Annals of oncology : official journal of the European Society for Medical Oncology [Ann Oncol] 2019 Dec 01; Vol. 30 (12), pp. 2013-2014.

Adjuvant bevacizumab in patients with melanoma at high risk of recurrence (AVAST-M): preplanned interim results from a multicentre, open-label, randomised controlled phase 3 study.

Autor: Corrie PG; Cambridge Cancer Trials Centre, Cambridge University Hospitals NHS Foundation Trust, Addenbrooke's Hospital, Cambridge, UK. Electronic address: pippa.corrie@addenbrookes.nhs.uk., Marshall A; Warwick Clinical Trials Unit, University of Warwick, Coventry, UK., Dunn JA; Warwick Clinical Trials Unit, University of Warwick, Coventry, UK., Middleton MR; Oxford National Institute for Health Research Biomedical Research Centre, Oxford, UK., Nathan PD; Medical Oncology, Mount Vernon Hospital, Northwood, Middlesex, UK., Gore M; Royal Marsden Hospital NHS Trust, London, UK., Davidson N; Oncology Research, Broomfield Hospital, Chelmsford, UK., Nicholson S; Oncology Department, Leicester Royal Infirmary, Leicester, UK., Kelly CG; Sir Bobby Robson Cancer Trials Research Centre, Freeman Hospital, Newcastle upon Tyne, UK., Marples M; Cancer Research, St James's University Hospital, Leeds, UK., Danson SJ; Academic Unit of Clinical Oncology, Weston Park Hospital, Sheffield, UK., Marshall E; Cancer and Palliative Care, St Helen's Hospital, St Helens, UK., Houston SJ; Oncology Department, Royal Surrey County Hospital, Surrey, UK., Board RE; Oncology Department, Royal Preston Hospital, Preston, UK., Waterston AM; Clinical Trials Unit, Beatson West of Scotland Cancer Centre, Glasgow, UK., Nobes JP; Clinical Oncology, Norfolk and Norwich University Hospital, Norwich, UK., Harries M; Guy's and St Thomas' Hospital, London, UK., Kumar S; Velindre Cancer Centre, Cardiff, UK., Young G; Cambridge Cancer Trials Centre/Cambridge Clinical Trials Unit-Cancer Theme, Addenbrooke's Hospital, Cambridge, UK., Lorigan P; Deptartment of Medical Oncology, Christie Hospital, Manchester, UK.

Publikováno v: The Lancet. Oncology [Lancet Oncol] 2014 May; Vol. 15 (6), pp. 620-30. Date of Electronic Publication: 2014 Apr 15.